arrow
L

Laura Leyva

servicio andaluz de salud
H指数:32
被引数:3,185

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

DEVELOPMENT OF A PROFICIENCY TESTING PLATFORM FOR ADVANCED THERAPIES MEDICINAL PRODUCTS (ATMPs)

高级治疗药物产品(ATMPs)能力验证平台的发展

2026-02-240
OAAI
Adipose-derived mesenchymal stem cells for the treatment of Amyotrophic Lateral Sclerosis. A phase I/II safety and efficacy clinical trial

脂肪来源间充质干细胞治疗肌萎缩侧索硬化症。一项I/II期安全性与有效性临床试验

2025-10-080
OAAI
Discovery and early validation of serum protein signatures in untreated multiple sclerosis patients: identification of candidate biomarkers for diagnosis and stratification

未治疗多发性硬化患者血清蛋白签名的发现与早期验证:用于诊断和分层的候选生物标志物的鉴定

2025-08-210
OA
Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment
2021-12-167
OAAI
Evaluation of the effectiveness of a new cryopreservation system based on a two-compartment vial for the cryopreservation of cell therapy products
2021-08-013
OAAI
A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells
2020-02-266
OAAI
Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease (Publication with Expression of Concern)
2019-06-0645
OAAI
Genome-wide significant association with seven novel multiple sclerosis risk loci
2015-10-1636
OAAI